Sean P. McConnell's articles Life Sciences Sanofi Abandons Licensing Deal With Maze Therapeutics After FTC Challenges The Proposed Transaction – Duane Morris Life Sciences Regulation On December 11, 2023, Sanofi launched a assertion that it’s going to terminate its proposed $755 million licensing settlement with Maze Therapeutics (Maze) shortly after the Federal Commerce Fee (FTC) issued an administrative grievance and approved submitting a grievance for preliminary injunction in the US District Court docket for the District […] Written by Sean P. McConnell March 27, 2024March 27, 2024 Saving Bookmark this article Bookmarked Life Sciences FTC Issues Policy Statement Cautioning Branded Drug Companies Against Improper Orange Book Listings – Duane Morris Life Sciences Law Duane Morris Takeaways: On Thursday September 14, 2023, the FTC issued a policy statement warning brand drug companies that improper listing of patents in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the “Orange Book” could violate Section 5 of the FTC Act. The Hatch-Waxman Act […] Written by Sean P. McConnell October 22, 2023October 22, 2023 Saving Bookmark this article Bookmarked
Life Sciences Sanofi Abandons Licensing Deal With Maze Therapeutics After FTC Challenges The Proposed Transaction – Duane Morris Life Sciences Regulation On December 11, 2023, Sanofi launched a assertion that it’s going to terminate its proposed $755 million licensing settlement with Maze Therapeutics (Maze) shortly after the Federal Commerce Fee (FTC) issued an administrative grievance and approved submitting a grievance for preliminary injunction in the US District Court docket for the District […] Written by Sean P. McConnell March 27, 2024March 27, 2024 Saving Bookmark this article Bookmarked
Life Sciences FTC Issues Policy Statement Cautioning Branded Drug Companies Against Improper Orange Book Listings – Duane Morris Life Sciences Law Duane Morris Takeaways: On Thursday September 14, 2023, the FTC issued a policy statement warning brand drug companies that improper listing of patents in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the “Orange Book” could violate Section 5 of the FTC Act. The Hatch-Waxman Act […] Written by Sean P. McConnell October 22, 2023October 22, 2023 Saving Bookmark this article Bookmarked
